A Potential Therapeutic Approach for Cisplatin-Induced Hearing Loss
Shao Wei Hu,Lei Han,Yilai Shu
DOI: https://doi.org/10.1016/j.omtn.2024.102207
2024-01-01
Abstract:Cisplatin is a highly effective anti-tumor drug that is often used to treat a variety of cancers, such as ovarian, cervical, and brain cancers. However, cisplatin can cause serious side effects, such as ototoxicity. Clinically, chemotherapy with cisplatin often causes permanent inner ear damage, thereby leading to progressive, bilateral, and irreversible hearing loss in patients. One mechanism underlying cisplatin-induced ototoxicity is the excessive production and accumulation of reactive oxygen species (ROS) and the ensuing apoptosis of hair cells (HCs) and spiral ganglion neurons (SGNs). Several molecules that can prevent excessive ROS or apoptosis have been identified for the treatment of cisplatin-induced ototoxicity.1Brock P.R. Maibach R. Childs M. Rajput K. Roebuck D. Sullivan M.J. Laithier V. Ronghe M. Dall'Igna P. Hiyama E. et al.Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.N. Engl. J. Med. 2018; 378: 2376-2385Crossref PubMed Scopus (201) Google Scholar,2Thakur N.S. Rus I. Sparks E. Agrahari V. Dual stimuli-responsive and sustained drug delivery NanoSensoGel formulation for prevention of cisplatin-induced ototoxicity.J. Control. Release. 2024; 368: 66-83Crossref Scopus (0) Google Scholar However, since chemotherapy often involves several cycles of treatment, the short half-life of anti-ototoxic drugs limits their therapeutic effects within the cochlea.3Araya C.E. Fennell R.S. Neiberger R.E. Dharnidharka V.R. Sodium thiosulfate treatment for calcific uremic arteriolopathy in children and young adults.Clin. J. Am. Soc. Nephrol. 2006; 1: 1161-1166Crossref PubMed Scopus (87) Google Scholar Moreover, repeated injection of anti-ototoxic drugs is inconvenient and could cause adverse local reactions. Thus, more permanent anti-ototoxic treatment strategies are necessary. Gene therapy is a promising strategy that offers durable efficacy with one-time administration and may revolutionize the treatment of many diseases, such as ear diseases, eye diseases, and blood disorders. Currently, adeno-associated viruses (AAVs), adenoviruses, lentiviruses (LVs), and retroviruses have been developed as delivery vehicles in gene therapy. Viral vectors are highly efficient at transfecting cells, and in general, viral vector-mediated gene therapy provides relatively strong and long-term expression of therapeutic transgenes. Moreover, many gene therapy clinical trials have used viral vectors as delivery tools.4Wei Hu S. Ding T. Tang H. Guo H. Cui W. Shu Y. Nanobiomaterial vectors for improving gene editing and gene therapy.Mater. Today. 2023; 66: 114-136Crossref Scopus (9) Google Scholar,5Lv J. Wang H. Cheng X. Chen Y. Wang D. Zhang L. Cao Q. Tang H. Hu S. Gao K. et al.AAV1-hOTOF gene therapy for autosomal recessive deafness 9: a single-arm trial.Lancet. 2024; https://doi.org/10.1016/S0140-6736(23)02874-XAbstract Full Text Full Text PDF PubMed Scopus (8) Google Scholar In a recent study published in Molecular Therapy Nucleic Acids, Nassauer et al. developed a gene therapy approach to protect cochlear cells from cisplatin-induced toxicity by using third-generation self-inactivating (SIN) LV vectors in vitro and in vivo.6Nassauer L. Staecker H. Huang P. Renslo B. Goblet M. Harre J. Warnecke A. Schott J.W. Morgan M. Galla M. Schambach A. Protection from cisplatin-induced hearing loss with lentiviral vector-mediated ectopic expression of the anti-apoptotic protein BCL-XL.Mol. Ther. Nucleic Acids. 2024; 35102157Abstract Full Text Full Text PDF Scopus (0) Google Scholar Their preclinical data suggest that gene therapy has the potential to be translated to clinical use in cancer patients. Nassauer et al. first confirmed that cisplatin can significantly increase ROS generation in HC-like House Ear Institute-organ of Corti 1 (HEI-OC1) cells and lead to cumulative cytotoxicity. To obtain the candidate molecules that could combat cisplatin-induced ototoxicity, they performed a small-scale screening that included the antioxidant enzymes superoxide dismutase 1 (SOD1), catalase (CAT), and glutathione peroxidase (GPX1) as well as the anti-apoptotic proteins B cell lymphoma 2 (BCL-2) and B cell lymphoma-extra large (Bcl-xl). Then they packaged the transgenes of the aforementioned molecules into LV vectors and tested their anti-ototoxic potential in HEI-OC1 cells (Figure 1). The first set of experiments assessed the effects of SIN LV vectors overexpressing human codon-optimized SOD1, CAT, or GPX1 on cisplatin-induced ROS and cell death. The results revealed that none of the SIN LV vectors overexpressing antioxidant enzymes affected ROS production or cell death in HEI-OC1 cells. Next, the authors examined the impact of BCL-2 and Bcl-xl on cisplatin-induced cell death. Compared to the vector control, SIN LV vectors expressing a codon-optimized version of human BCL-2 (LV.BCL-2) or murine BCL-XL (LV.BCL-XL) significantly decreased apoptotic cell death in cisplatin-treated HEI-OC1 cells. However, LV.BCL-XL was more effective at reducing cisplatin-induced cell death than LV.BCL-2; thus, only LV.BCL-XL was assessed in further experiments. Utilizing similar methods, the authors demonstrated that cisplatin treatment can induce cell death in SGN-like phoenix auditory neurons and neuroprogenitors in vitro. Cisplatin treatment also induced morphological changes in phoenix auditory neurons, reduced neuroprogenitor sphere formation, and altered neuroprogenitor sphere morphology. Compared with the vector control, LV.BCL-XL prevented these toxic effects in both phoenix auditory neurons and phoenix auditory neuroprogenitors. Further experiments in primary SGN cells and rat cochlear explants revealed that cisplatin induced cell death in primary SGNs and destroyed the normal HC organization of rat cochlear explants; the administration of LV.BCL-XL also prevented these negative effects. Altogether, these results indicate that the antiapoptotic effects mediated by LV.BCL-XL ultimately decreased the cytotoxicity of cisplatin treatment in HC-like cells, SGN-like cells, primary SGNs, and primary HCs. More importantly, the authors verified the protective effects of BCL-XL protein in a cisplatin challenge experiment in vivo. LV.BCL-XL was administered at post-natal day 30 via canalostomy into one ear of each wild-type C57BL/6 mouse. Auditory brainstem response (ABR) measurements revealed this manipulation did not affect the hearing capacity of the mice. Five days later, 4 mg/kg cisplatin was administered intraperitoneally for five consecutive days. Cisplatin treatment induced damage to outer hair cells (OHCs) and hearing loss in mice that did not receive LV.BCL-XL gene therapy, whereas OHCs in the cochlear base and high-frequency hearing were protected in mice that received LV.BCL-XL gene therapy (Figure 1). It is worth noting that, similar to other studies, Nassauer et al. used local administration of LV.BCL-XL to the inner ear instead of systemic administration. Local administration to the inner ear is typically utilized because the cochlea is relatively anatomically isolated from neighboring organs and is separated from systemic blood circulation through the blood-labyrinth barrier. This unique structure maintains immune privilege within the cochlea and minimizes off-target transfection. Additionally, the blood-labyrinth barrier could prevent systemically administered gene therapy drugs from reaching target cells in the inner ear. Overall, this very well-designed study demonstrates the ability of a novel preclinical gene therapy strategy to protect cochlear cells from cisplatin-induced ototoxicity in vitro, ex vivo, and in vivo. Nevertheless, several limitations need to be further addressed before clinical translation of LV.BCL-XL gene therapy. The first limitation is the choice of viral vector. Although SIN LV has several advantageous characteristics, like high packaging capacity and low immunogenicity, LVs are integrating vectors that could potentially induce insertional mutagenesis.4Wei Hu S. Ding T. Tang H. Guo H. Cui W. Shu Y. Nanobiomaterial vectors for improving gene editing and gene therapy.Mater. Today. 2023; 66: 114-136Crossref Scopus (9) Google Scholar Alternatively, AAVs are non-integrating vectors with high transfection efficiency in a large number of cell types and have the potential to provide long-term expression of therapeutic transgenes such as BCL-XL. Presently, multiple AAV serotypes enable efficient transfection of various types of inner ear cells. The second limitation is the expression region of the BCL-XL protein, as the ectopic expression of protein driven by ubiquitous promoters (e.g., cytomegalovirus immediate‑early enhancer/chicken β‑actin (CAG) and cytomegalovirus (CMV) promoters) may induce cytotoxicity. Administration of LV.BCL-XL into the ear via canalostomy will express the BCL-XL protein in almost all kinds of inner ear cells, whereas combining a cell type-specific viral vector (e.g., AAV.PHP.eB) with a cell type-specific promoter (e.g., the Myo15 promoter7Wang H. Xun M. Tang H. Zhao J. Hu S. Zhang L. Lv J. Wang D. Chen Y. Liu J. et al.Hair cell-specific Myo15 promoter-mediated gene therapy rescues hearing in DFNB9 mouse model.Mol. Ther. Nucleic Acids. 2024; 35102135Abstract Full Text Full Text PDF Scopus (1) Google Scholar) will restrict the expression range of transgenes and further increase the safety of gene therapy. In conclusion, reducing apoptosis by overexpressing the anti-apoptotic protein BCL-XL ameliorated cisplatin-induced cytotoxicity in HEI-OC1 cells, phoenix auditory neurons, primary SGN cultures, and cochlear explants. By contrast, reducing oxidative stress by overexpressing antioxidant enzymes (i.e., SOD1, CAT, or GPX1) failed to protect HEI-OC1 cells from cisplatin-induced toxicity. Moreover, in vivo application of the LV.BCL-XL vector increased the HC survival rate and protected cisplatin-treated mice from high-frequency hearing loss. These results revealed that preventing apoptosis is more effective than reducing oxidative stress in alleviating cisplatin-induced ototoxicity. Research in our laboratory is supported by the National Science Fund for Distinguished Young Scholars (82225014) and the China Postdoctoral Science Foundation (2022M720780). S.W.H., L.H., and Y.S. conceived and wrote this commentary. The authors declare no competing interests.